Fundamental Analysis of KEROS THERAPEUTICS INC(NASDAQ:KROS) stock

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to KROS. KROS was compared to 568 industry peers in the Biotechnology industry. KROS has a great financial health rating, but its profitability evaluates not so good. KROS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

KROS had negative earnings in the past year.

KROS had a negative operating cash flow in the past year.

In the past 5 years KROS always reported negative net income.

KROS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -31.34%, KROS is doing good in the industry, outperforming 66.37% of the companies in the same industry.

KROS has a Return On Equity of -34.08%. This is in the better half of the industry: KROS outperforms 76.81% of its industry peers.

		Industry Rank	Sector Rank
ROA	-31.34%
ROE	-34.08%
ROIC	N/A

ROA(3y)-32.82%

ROA(5y)-45.5%

ROE(3y)-35.98%

ROE(5y)-518.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KROS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KROS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for KROS has been increased compared to 1 year ago.

The number of shares outstanding for KROS has been increased compared to 5 years ago.

There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 8.08 indicates that KROS is not in any danger for bankruptcy at the moment.

KROS has a better Altman-Z score (8.08) than 84.25% of its industry peers.

KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	8.08

ROIC/WACCN/A

WACC11.78%

2.3 Liquidity

KROS has a Current Ratio of 19.03. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 19.03, KROS belongs to the best of the industry, outperforming 94.51% of the companies in the same industry.

A Quick Ratio of 19.03 indicates that KROS has no problem at all paying its short term obligations.

KROS's Quick ratio of 19.03 is amongst the best of the industry. KROS outperforms 94.51% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	19.03
Quick Ratio	19.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for KROS have decreased by -5.25% in the last year.

KROS shows a strong growth in Revenue. In the last year, the Revenue has grown by 6410.00%.

The Revenue for KROS have been decreasing by -56.77% on average. This is quite bad

EPS 1Y (TTM)-5.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.02%

Revenue 1Y (TTM)6410%

Revenue growth 3YN/A

Revenue growth 5Y-56.77%

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KROS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.22% on average per year.

KROS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 744.43% yearly.

EPS Next Y-3.83%

EPS Next 2Y-6.48%

EPS Next 3Y-3.53%

EPS Next 5Y8.22%

Revenue Next Year12566.5%

Revenue Next 2Y183.81%

Revenue Next 3Y1554.17%

Revenue Next 5Y744.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KROS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

KROS's earnings are expected to decrease with -3.53% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-6.48%

EPS Next 3Y-3.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

KROS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KEROS THERAPEUTICS INC

NASDAQ:KROS (12/18/2024, 3:48:59 PM)

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap729.18M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.34%
ROE	-34.08%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	19.03
Quick Ratio	19.03
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-5.25%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-3.83%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)6410%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

KEROS THERAPEUTICS INC (KROS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens